Welcome to our dedicated page for Bleichroeder Acquisition II SEC filings (Ticker: BBCQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bleichroeder Acquisition Corp. II filings document the company’s SPAC structure, Nasdaq-listed securities, material-event reports, governance changes, and capital-structure disclosures. The records identify the issuer as a Cayman Islands exempted company with Class A ordinary shares under BBCQ and redeemable warrants under BBCQW.
The company’s 8-K disclosures include board and management changes, director appointments, and other material-event reporting. Its filings also state emerging growth company status and describe the warrant terms and ordinary-share structure that define the public securities associated with the blank-check issuer.
Bleichroeder Acquisition Corp. II announced a proposed Business Combination to merge with Pasqal Holding SAS. The agreement values the combined company at $2 billion pre-money, includes a $200 million convertible financing and up to $289 million of additional proceeds dependent on investor redemptions. The transaction assigns a pro forma market capitalization of approximately $2.6 billion and is expected to close in the second half of the year. The merger will be submitted to Bleichroeder shareholders and Bleichroeder intends to file a Registration Statement on Form F-4; consummation is subject to shareholder and regulatory approvals.
Bleichroeder Acquisition Corp. II disclosed a March 4, 2026 LinkedIn communication from Pasqal Holding SAS about their proposed business combination and related financing and corporate plans.
Pasqal described accelerated commercialization, geographic expansion across Europe, Asia Pacific, North America and the Middle East, and stated an initial NASDAQ listing expected in 2026. The communication includes standard forward-looking statements and notes that a Form F-4 registration statement and definitive proxy/prospectus will be filed; shareholder approval and regulatory conditions apply, including that consummation is subject to required regulatory approvals.